Explore Video

Treatment intensification for metastatic hormone-sensitive prostate cancer (mHSPC) involves combining multiple therapies to improve patient outcomes.

PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.

In this video, Dr. Floege talks about the mechanisms of vascular calcifications in patients at high risk of CKD and measures to prevent or reverse the same.

Toripalimab, a PD-1 inhibitor, has emerged as a promising treatment for metastatic or locally advanced recurrent NPC. Toripalimab can significantly improve response rates and prolong survival in patients who have progressed on previous therapies

Maintenance therapy with Midostaurin in AML patients with FLT3 mutations has shown potential in improving event-free survival and reducing relapse risk.

Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.

MRD-directed maintenance therapy in multiple myeloma tailors treatment based on minimal residual disease (MRD) status, aiming to optimize outcomes while minimizing overtreatment.

Iron chelation therapy (ICT) in MDS is used to manage iron overload from frequent blood transfusions. It involves identifying patients who would benefit most, monitoring iron levels, and managing side effects of chelators

Bispecific antibodies, particularly T-cell-engaging ones, are emerging as effective therapies for relapsed/refractory multiple myeloma. Prophylactic measures and tailored dosing strategies are crucial for minimizing adverse effects.

Biosimilars are biologic medicines that are highly similar to an FDA-approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency.